Description

Simple

A medication used to treat asthma, certain skin conditions, and a runny nose.

Clinical

A glucocorticoid used to treat asthma, inflammatory pruritic dermatoses, and nonallergic rhinitis.

Overview

Fluticasone propionate is a synthetic glucocorticoid[9,10][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[9,10][FDA Label]. Fluticasone propionate was first approved in 1990[7].

Pharmacology

Indication

Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label]as well as inflammatory and pruritic dermatoses[9]. Fluticasone prop... Read more

Pharmacodynamic

Systemically, fluticasone propionate activates glucocorticoid receptors, and inhibits lung eosinophilia in rats[10][FDA Label]. Fluticasone propionate as a topical formulation is also... Read more

Mechanism of action

Fluticasone propionate works through an unknown mechanism to affect the action of various cell types and mediators of inflammation[10]. Fluticasone propionate activates glucocorticoid... Read more

Absorption

Intranasal bioavailability of fluticasone propionate is Read more

Protein binding

Fluticasone propionate is 99% protein bound in serum[10]. Topical fluticasone propionate is only 91% protein bound in serum however[ Read more

Volume of distribution

The volume of distribution of intravenous fluticasone propionate is 4.2L/kg[10][FDA Label]. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577... Read more

Clearance

1093mL/min for fluticasone propionate[10]. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration[ Read more

Half life

7.8 hours for intravenous fluticasone propionate[10][FDA Label]. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hou... Read more

Route of elimination

Fluticasone propionate is mainly eliminated in the feces with Read more

Toxicity

Fluticasone propionate's use in specific populations has not been well studied[10]. Fluticasone propionate is not carcinogenic, mutagenic, or clastogenic, nor did it affect fertility i... Read more

Adverse Effects

Contraindications

  • Route:
    • Nasal
  • Dose Form:
    • Spray
  • Hypersensitivity:
    • true
  • Sex Group: all
  • Regions: US
  • Above Age:
    • Amount: 4
    • Unit: year
  • Route:
    • Topical
  • Dose Form:
    • Ointment
  • Hypersensitivity:
    • true
  • Sex Group: all
  • Regions: US
  • Excluded Age Groups:
    • pediatric
  • Route:
    • Respiratory (inhalation)
  • Dose Form:
    • Aerosol
  • Sex Group: all
  • Regions: US
  • Above Age:
    • Amount: 4
    • Unit: year
  • Patient Conditions:
      • Name: Acute Asthma
      • Drugbank Id: DBCOND0035896
      • Modification Of:
        • Base:
          • Name: Asthma
          • Drugbank Id: DBCOND0013565
        • Severity:
          • Includes:
            • acute
  • Route:
    • Respiratory (inhalation)
  • Dose Form:
    • Aerosol
  • Sex Group: all
  • Regions: US
  • Above Age:
    • Amount: 4
    • Unit: year
  • Patient Conditions:
      • Name: Status Asthmaticus
      • Drugbank Id: DBCOND0001831
  • Route:
    • Respiratory (inhalation)
  • Dose Form:
    • Aerosol
  • Hypersensitivity:
    • true
  • Sex Group: all
  • Regions: US
  • Above Age:
    • Amount: 4
    • Unit: year

Food Interactions

  • Avoid alcohol. Drowsiness may be exacerbated when patients taking fluticasone propionate nasal spray also consume alcohol.

Interactions

Type in a drug name to check for interaction with Fluticasone propionate
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The serum concentration of (R)-warfarin can be increased when it is combined with Fluticasone propionate.
(S)-Warfarin
The serum concentration of (S)-Warfarin can be increased when it is combined with Fluticasone propionate.
1-Testosterone
The risk or severity of edema formation can be increased when 1-Testosterone is combined with Fluticasone propionate.
1,10-Phenanthroline
The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Fluticasone propionate.
16-Bromoepiandrosterone
The risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Fluticasone propionate.
19-norandrostenedione
The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluticasone propionate.
1alpha-Hydroxyvitamin D5
The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Fluticasone propionate.
1alpha,24S-Dihydroxyvitamin D2
The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Fluticasone propionate.
2-Methoxyethanol
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 2-Methoxyethanol.
2,4-thiazolidinedione
The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with 2,4-thiazolidinedione.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarin
Fluticasone propionate may increase the anticoagulant activities of 4-hydroxycoumarin.
4-Hydroxytestosterone
The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluticasone propionate.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 4-Methoxyamphetamine.
5-androstenedione
The risk or severity of edema formation can be increased when 5-androstenedione is combined with Fluticasone propionate.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
10 References
  1. 1 . Allen A, Bareille PJ, Rousell VM: Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013 Jan;52(1):37-42. doi: 10.1007/s40262-012-0021-x.PubMed: 23184737
  2. 2 . Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L: Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013 Oct;7(4):397-406. doi: 10.1111/crj.12026. Epub 2013 Jun 5.PubMed: 23578031
  3. 3 . Phillipps GH: Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med. 1990 Nov;84 Suppl A:19-23.PubMed: 2287791
  4. 4 . Harding SM: The human pharmacology of fluticasone propionate. Respir Med. 1990 Nov;84 Suppl A:25-9.PubMed: 2287792
  5. 5 . Crim C, Pierre LN, Daley-Yates PT: A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001 Sep;23(9):1339-54.PubMed: 11589253
  6. 6 . Choi JS, Han JY, Kim MY, Velazquez-Armenta EY, Nava-Ocampo AA: Pregnancy outcomes in women using inhaled fluticasone during pregnancy: a case series. Allergol Immunopathol (Madr). 2007 Nov-Dec;35(6):239-42.PubMed: 18047814
  7. 7 . FDA Approved Drug Products December 1990 Link
  8. 8 . FDA Approved Drugs: Dymista nasal spray Link
  9. 9 . Fluticasone Propionate (Cutivate) Ointment FDA Label File
  10. 10 . Fluticasone Propionate (Flonase) Nasal Spray FDA Label File